Model N Inc. provides revenue management solutions for life sciences and technology companies including applications for configure, price, quote (CPQ), rebates management and regulatory compliance. The company is accelerating its transition of revenue management to cloud. The company is making steady progress in its transformation to a Software-as-a-Service based model. The company provides Revenue Cloud for Pharma, Med Tech, High-Tech Manufacturing and Semiconductors & Components. Model N's revenue cloud offerings provide higher Return on Investment as well as plug gaps in the end-to-end revenue management process that legacy systems fail to do. Revenue Cloud suite is a software-as-a-service based subscriptions tool developed to automate processes of Revenue Management lifecycle. The suite includes products for CPQ, Contract Lifecycle Management and Rebates Management....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 2 May 2026
2016-10-19 00:00:00 Wednesday ET

India's equivalent to Warren Buffett in America, Rakesh Jhunjhunwala, offers several key lessons for stock market investors: When the press o
2020-09-03 10:26:00 Thursday ET

Agile business firms beat the odds by building faster institutional reflexes to anticipate plausible economic scenarios. Christopher Worley, Thomas Willi
2027-04-30 12:31:00 Friday ET

In recent years, the current AI-driven stock market rally may or may not turn out to be another major asset bubble in global human history. For the pract
2020-05-07 08:26:00 Thursday ET

Disruptive innovators often apply their 5 major pragmatic skills in new blue-ocean niche discovery and market share dominance. Jeff Dyer, Hal Gregersen,
2026-10-31 12:38:00 Saturday ET

Today tech titans and billionaires continue to reshape global pharmaceutical investments for both better healthspan and longer lifespan. We discuss, desc
2017-11-27 07:39:00 Monday ET

Is it anti-competitive and illegal for passive indexers and mutual funds to place large stock bets in specific industries with high market concentration? Ha